These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients. Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603 [TBL] [Abstract][Full Text] [Related]
12. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series. Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076 [TBL] [Abstract][Full Text] [Related]
13. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
14. How accurate is Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066 [TBL] [Abstract][Full Text] [Related]
15. The use of Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165 [TBL] [Abstract][Full Text] [Related]
16. PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study. Francolini G; Banini M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Roghi M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L Prostate; 2023 Sep; 83(12):1201-1206. PubMed ID: 37290915 [TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035 [TBL] [Abstract][Full Text] [Related]
18. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958 [TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy. Harsini S; Wilson D; Saprunoff H; Allan H; Gleave M; Goldenberg L; Chi KN; Kim-Sing C; Tyldesley S; Bénard F Cancer Imaging; 2023 Mar; 23(1):27. PubMed ID: 36932416 [TBL] [Abstract][Full Text] [Related]
20. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]